<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-05-02">2 May 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Professor</roleName><forename type="first">Patrizio</forename><surname>Lancellotti</surname></persName>
							<email>plancellotti@chu.ulg.ac.be</email>
							<affiliation key="aff0">
								<orgName type="department">Imaging Cardiology</orgName>
								<orgName type="institution" key="instit1">University of Liège Hospital</orgName>
								<orgName type="institution" key="instit2">GIGA Cardiovascular Science</orgName>
								<orgName type="institution" key="instit3">Heart Valve Clinic</orgName>
								<address>
									<settlement>Liège</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Gruppo Villa Maria Care and Research</orgName>
								<orgName type="institution" key="instit2">Anthea Hospital</orgName>
								<address>
									<settlement>Bari</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maurizio</forename><surname>Galderisi</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Advanced Biomedical Sciences</orgName>
								<orgName type="institution">Federico II University Hospital</orgName>
								<address>
									<settlement>Naples</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Erwan</forename><surname>Donal</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">LTSI-INSERM U 1099</orgName>
								<address>
									<settlement>Cardiologie</settlement>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution" key="instit1">CHU Rennes</orgName>
								<orgName type="institution" key="instit2">Université Rennes 1</orgName>
								<address>
									<settlement>Rennes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thor</forename><surname>Edvardsen</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Oslo University Hospital</orgName>
								<address>
									<settlement>Rikshospitalet</settlement>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="institution">University of Oslo</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Centre of Cardiological Innovation</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bogdan</forename><forename type="middle">A</forename><surname>Popescu</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Institute of Cardiovascular Diseases &apos;Prof. Dr. C. C. Iliescu&apos;</orgName>
								<orgName type="institution">University of Medicine and Pharmacy &apos;Carol Davila&apos;-Euroecolab</orgName>
								<address>
									<settlement>Bucharest</settlement>
									<country key="RO">Romania</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dimitrios</forename><surname>Farmakis</surname></persName>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Cardio-Oncology Clinic</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<orgName type="laboratory">Heart Failure Unit</orgName>
								<orgName type="institution" key="instit1">University Hospital &apos;Attikon&apos;</orgName>
								<orgName type="institution" key="instit2">National and Kapodistrian University of Athens</orgName>
								<address>
									<settlement>Athens</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gerasimos</forename><surname>Filippatos</surname></persName>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Cardio-Oncology Clinic</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<orgName type="laboratory">Heart Failure Unit</orgName>
								<orgName type="institution" key="instit1">University Hospital &apos;Attikon&apos;</orgName>
								<orgName type="institution" key="instit2">National and Kapodistrian University of Athens</orgName>
								<address>
									<settlement>Athens</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gilbert</forename><surname>Habib</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution" key="instit1">URMITE</orgName>
								<orgName type="institution" key="instit2">Aix Marseille Université</orgName>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department">Cardiology Department</orgName>
								<orgName type="institution" key="instit1">APHM</orgName>
								<orgName type="institution" key="instit2">La Timone Hospital</orgName>
								<address>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Chiara</forename><surname>Lestuzzi</surname></persName>
							<affiliation key="aff12">
								<orgName type="laboratory">Centro di Riferimento Oncologico (CRO)</orgName>
								<orgName type="institution">National Cancer Institute</orgName>
								<address>
									<settlement>Aviano</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ciro</forename><surname>Santoro</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Advanced Biomedical Sciences</orgName>
								<orgName type="institution">Federico II University Hospital</orgName>
								<address>
									<settlement>Naples</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marie</forename><surname>Moonen</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Imaging Cardiology</orgName>
								<orgName type="institution" key="instit1">University of Liège Hospital</orgName>
								<orgName type="institution" key="instit2">GIGA Cardiovascular Science</orgName>
								<orgName type="institution" key="instit3">Heart Valve Clinic</orgName>
								<address>
									<settlement>Liège</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Guy</forename><surname>Jerusalem</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution" key="instit1">CHU Sart Tilman Liège</orgName>
								<orgName type="institution" key="instit2">University of Liège</orgName>
								<address>
									<settlement>Liège</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maryna</forename><surname>Andarala</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">ESC EORP Department</orgName>
								<address>
									<settlement>Sophia Antipolis</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medicine Göttingen (UMG)</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="department">DZHK (German Center for Cardiovascular Research)</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff17">
								<orgName type="department" key="dep1">Division of Cardiology and Metabolism -Heart Failure</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine &amp; Cardiology; and Berlin-Brandenburg Center for Regenerative Therapies (BCRT)</orgName>
								<orgName type="institution" key="instit1">Cachexia &amp; Sarcopenia</orgName>
								<orgName type="institution" key="instit2">Charité University Medicine</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution" key="instit1">EACVI/HFA COT Registry</orgName>
								<orgName type="institution" key="instit2">University Hospital Sart Tilman</orgName>
								<address>
									<postCode>B-4000</postCode>
									<settlement>Liège</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-05-02">2 May 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">7CEC47A51A8C4D3DA17F80CC2FA39F61</idno>
					<idno type="DOI">10.1002/ehf2.12162</idno>
					<note type="submission">Received: 25 January 2017; Accepted: 8 March 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:36+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Anticancer drug-related cardiotoxicity</term>
					<term>Targeted therapy</term>
					<term>Heart failure</term>
					<term>Cardiac imaging</term>
					<term>Arterial hypertension</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Aims European Association of Cardiovascular Imaging/Heart Failure Association Cardiac Oncology Toxicity Registry was launched in October 2014 as a European Society of Cardiology multicentre registry of breast cancer patients referred to imaging laboratories for routine surveillance, suspected, or confirmed anticancer drug-related cardiotoxicity (ADRC).</s><s>After a pilot phase (1 year recruitment and 1 year follow-up), some changes have been made to the protocol (version 1.0) and electronic case report form.</s><s>Methods and results Main changes of the version 2.0 concerned exclusion criteria, registry duration, and clarification of the population characteristics.</s><s>Breast cancer radiotherapy has been removed as an exclusion criterion, which involves now only history of a pre-chemotherapy left ventricular dysfunction.</s><s>The period for long-term registry recruitment has been reduced (December 2017), but the target study population was extended to 3000 patients.</s><s>The characteristics of the population are now better defined: patients seen in an imaging lab, which will include patients undergoing chemotherapy with associated targeted therapy or no targeted therapy, at increased risk of ADRC.</s><s>In total, 1294 breast cancer patients have been enrolled, and 783 case report forms locked from October 2014 to November 2016.</s><s>Of these, 481 (61.4%) were seen at first evaluation and 302 (38.6%) while on oncologic treatment with anticancer drugs.</s><s>Fifty-two patients (17.2%) were not in targeted therapies, 191 (63.3%) were ongoing targeted therapy, and 59 (19.5%) had completed it.</s><s>Twenty-three (2.9%) patients had a suspected diagnosis and 35 (4.5%) a confirmed diagnosis of ADRC.</s><s>Arterial hypertension was the most prevalent cardiovascular risk factor (29.2%) followed by diabetes (6.1%).</s><s>Previous history of heart failure accounted for 0.5%, whereas previous cardiac disease was identified in 6.3% of population.</s><s>Conclusion The changes of the original protocol of the COT Registry and first update allow a first glance to the panorama of cardiovascular characteristics of breast cancer patients enrolled.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The need for a registry on drug-related cardiotoxicity in breast cancer patients</s></p><p><s>In relation with important advances in adjuvant therapy drugs (anthracyclines, taxanes, and trastuzumab), both disease-free survival and mortality rates of cancer patients have been substantially improved in the last decade. <ref type="bibr" target="#b0">1</ref></s><s>In parallel, the increased survival has brought the problem of anticancer drug-related cardiotoxicity (ADRC) to the attention of both oncologists and cardiologists. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b2">3</ref></s><s>The European Society of Cardiology (ESC) timely created a task force for cancer treatments and cardiovascular toxicity, which has published in August 2016 a comprehensive position paper on this issue, under the auspices of the ESC Committee for Practice Guidelines. <ref type="bibr" target="#b4">4</ref> In this context, breast cancer-related ADRC, the most common cancer in women, <ref type="bibr" target="#b0">1</ref> is gaining increasing impact.</s><s>Age-adjusted 5 year survival of breast cancer patients is known to be about 79%. <ref type="bibr" target="#b4">4</ref> A variable proportion of these patients experience ADRC, which can develop during/after anthracycline therapy (cardiotoxicity type 1) or be related to the use of humanized monoclonal antibodies against extracellular domain of HER2, such as trastuzumab (cardiotoxicity type 2). <ref type="bibr" target="#b5">5</ref> These two kinds of cardiotoxicity may overlap in breast cancer patients, as these two different classes of drugs are usually administered sequentially.</s><s>Worthy of note, trastuzumab has shown to have a synergic effect on anthracycline's cardiotoxicity. <ref type="bibr" target="#b6">6</ref></s><s>o date, the poor data available on presentation and management of breast cancer patients with ADRC are mainly provided by clinical trials, which do not reflect the real world.</s><s>In addition, information on cardiac imaging and biomarker practice for the detection and follow-up of ADRC into clinical routine in Europe is limited.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Main objectives of the Cardiac Oncology Toxicity Registry</head><p><s>European Association of Cardiovascular Imaging/Heart Failure Association Cardiac Oncology Toxicity (COT) Registry was launched as a multicentre registry, part of the EURObservational Research Programme of the ESC of patients affected by breast cancer referred to imaging laboratories for routine surveillance, suspicion, or confirmation of ADRC.</s><s>It concerns a comprehensive data collection and evaluation of the current European practice in terms of diagnosis and management of ADRC in breast cancer patients.</s><s>The COT Registry has been designed to examine clinical signs and symptoms as well as cardiac imaging and treatment practices for ADRC in breast cancer patients in Europe.</s><s>The cardiac imaging exam actually provides an opportunity to collect clinical information and detects the onset, progression, or resolution of ADRC.</s><s>The imaging evaluation concerns mainly an echo exam, which is periodically repeated, including the assessment of standard parameters such as left ventricular (LV) ejection fraction, Doppler-derived diastolic parameters (E/A ratio, E velocity deceleration time, and E/e 0 ratio), left atrial volume and, optionally, global longitudinal strain according to American Society of Echocardiography/European Association of Cardiovascular Imaging Expert Consensus for Multi-Modality Imaging Evaluation of Adult Patients During and After Cancer Therapy. <ref type="bibr" target="#b7">7</ref></s><s>he main scopes of the COT Registry include the following: (i) definition of ADRC-related risk factors, clinical phenotypes, and epidemiology; (ii) determination of ADRC outcomes; (iii) report of asymptomatic/symptomatic ADRC rates; (iv) description of ADRC time course; (v) recording of current standards for diagnostic workup (cardiac imaging/ biomarkers) and clinical follow-up of those patients; (vi) assessment of treatment changes associated with ADRC and their influence on ADRC; (vii) description of cardioprotective drugs and other therapeutic approaches used for ADRC; and (viii) evaluation of treatment adherence to ESC Guidelines for overt heart failure (HF) or early asymptomatic LV dysfunction. <ref type="bibr" target="#b8">8</ref></s><s>Rationale and scopes of the COT Registry have been previously published. <ref type="bibr" target="#b9">9</ref></s><s>anges from the Cardiac Oncology Toxicity protocol first release</s></p><p><s>The COT Registry was launched in October 2014 and will last until December 2017 or until 3000 patients are included.</s><s>After passing through a first short-term pilot phase (1 year recruitment and 1 year follow-up), some changes have been made to the protocol and the electronic case report form (CRF) in order to improve data quality and allow a better analysis of the results.</s><s>The main protocol changes of the version 2.0 dated 1 October 2015 concerned:</s></p><p><s>• exclusion/inclusion criteria, • duration of the registry and study sample size, and • clarification on the definition of the study population.</s></p><p><s>The exclusion criterion of isolated breast cancer radiotherapy has been removed, so that the only exclusion concerns the history of a pre-chemotherapy LV dysfunction (LV ejection fraction &lt;50%).</s></p><p><s>The period for long-term registry recruitment has been reduced (December 2017 instead of June 2018), but the target study population has been extended to 3000 breast cancer patients instead of 700 ADRC, initially established in the protocol version 1.0.</s><s>The Executive Committee with the approval of the Oversight Committee of the EURObservational COT Registry: protocol update and preliminary results</s></p><p><s>Research Programme has reserved the chance to continue the registry going further the declared deadline.</s></p><p><s>Version 2.0 of the protocol better defines the characteristics of the study population.</s><s>Breast cancer patients seen in an imaging lab (echo or nuclear cardiology) for routine surveillance of LV function or suspected ADRC or confirmed LV dysfunction are enrolled in the registry.</s><s>Following these criteria, the study population will include patients undergoing chemotherapy with associated targeted therapy (e.g.</s><s>trastuzumab) or no targeted therapy, at increased risk of ADRC.</s></p><p><s>The outpatients' visits are performed according to the usual practice of the participating centres as established in the version 1.0.</s><s>However, the 1 month follow-up visit has been abolished in order to introduce in the protocol a scheduled 3 month follow-up visit after enrolment, which reflects the common clinical practice in European imaging laboratories.</s><s>Accordingly, data on morbidity and mortality at 3, 6, and 12 months after the entry visit will be collected.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Information on recruitment and preliminary results</head><p><s>The first patient visit of the COT Registry occurred in October 2014.</s><s>In 27 registered countries, 110 centres were registered in Europe and countries outside Europe such as Argentina, Brazil, Saudi Arabia, China, and India.</s><s>Among these, 17 countries  COT Registry: protocol update and preliminary results</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>315</head><p><s>(68%) and 58 centres (53%) are actually active.</s><s>The leading enrolling countries are Italy (51.2%) followed by Belgium (10.2%),</s><s>Saudi Arabia (7.7%), Portugal (6.6%), and Romania (5.3%).</s><s>Globally, 1294 breast cancer patients have been enrolled, and 783 CRFs locked (CRF can be locked when all oncologic and cardiologic parameters are collected for individual patients) making possible a preliminary analysis of the results (Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>Of these 783 patients, 481 (61.4%) were seen at their first evaluation, that is, referred to the cardiac imaging lab for a baseline (pre-anticancer drug therapy) evaluation, whereas 302 (38.6%) were already on oncologic treatment with anticancer drug therapy; in this latter group, 52 patients (17.2%) were not in targeted therapies (mainly anthracyclines), 191 (63.3%) were ongoing targeted therapy, and 59 (19.5%) had completed it (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>Table <ref type="table" target="#tab_1">2</ref> summarizes the hitherto population synthesis regarding the detected ADRC in the COT Registry: 23 (2.9%) patients had a suspected and 35 (4.5%) a confirmed diagnosis of ADRC.</s><s>In the overall population, arterial hypertension was the most prevalent cardiovascular risk factor (29.2%) followed by diabetes mellitus (6.5%), whereas smoking status (13.4%) and dyslipidemia (24.3%) appeared rarely.</s><s>Previous history of HF (before the beginning of anticancer drug therapy) accounted for 0.5%, whereas previous cardiac disease was identified in 6.3% of the study population (Figure <ref type="figure" target="#fig_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Implications</head><p><s>Changes of electronic CRF in version 2.0 of the COT Registry were performed to improve the data collection and provide the possibility of more comprehensive analyses and better interpretation of the results.</s><s>In particular, these changes reflect more appropriately the common clinical practice in European countries.</s><s>The inclusion of patients undergoing isolated breast cancer radiotherapy enlarges the sample size of the study population, again being much more representative of the breast cancer population in the real world.</s><s>Radiotherapy is in fact often associated with drug therapy in the management of these patients.</s><s>]<ref type="bibr" target="#b12">[12]</ref><ref type="bibr" target="#b13">[13]</ref> The analysis of preliminary results highlights the type and rate of ADRC as well as the prevalence of cardiovascular risk factors in the study population.</s></p><p><s>The combined rate of suspected and confirmed ADRC was 7.4%, a rate that should not be under evaluated.</s><s>This finding is valuable as it has been derived by real-world evidence.</s><s>This is actually an important advantage of a registry in comparison with clinical trials.</s><s>Data derived from clinical trials are expected to underestimate the 'true' frequency of HF in cancer patients for two main reasons: first, patients at risk of HF based on previous cardiac diseases are excluded; second, cancer trial participants who developed HF symptoms could drop out of chemotherapy trials without undergoing follow-up.</s><s>Even in epidemiologic studies, HF due to ADRC may be underestimated because of the long interval between chemotherapy and clinical findings.</s></p><p><s>Other important data involve the prevalence of cardiovascular risk factors observed in the study population of COT Registry.</s><s>The relatively high rate of arterial hypertension (29.3%) combined with the 24% rate of dyslipidemia and 5% rate of diabetes mellitus points out a possible common denominator of metabolic syndrome and cancer.</s><s>This association has already been reported, <ref type="bibr" target="#b14">14</ref> as insulin resistance is associated with HF. <ref type="bibr" target="#b15">15</ref> Arterial hypertension has previously been identified as one of the main factors for ADRC. <ref type="bibr" target="#b16">16,</ref><ref type="bibr" target="#b17">17</ref></s><s>The rate of previous cardiac disease was 6.3%, another finding, which confirms previous investigations. <ref type="bibr" target="#b16">16</ref></s><s>The increasing number of the COT study population might influence the determinants of ADRC because of factors such as age, previous cardiac irradiation, and especially coronary artery disease.</s></p><p><s>In conclusion, changes of the original protocol of the COT Registry and first update allow a first glance to the panorama of cardiovascular characteristics of breast cancer patients enrolled.</s><s>A larger population will be needed to provide information on outcome of ADRC, to describe the time course of ADRC according to the beginning of chemotherapy, and to design the exact picture of the European standards for diagnostic workup and clinical follow-up of these patients as well as the treatment adherence to ESC Guidelines for overt and asymptomatic HF.</s><s>Worthy of note, final release and completion of the COT Registry will represent a possible model to collect cardiac information on diagnosis and management of ADRC in other types of tumours.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Percentage of patients on anticancer drug therapy (upper panel) and of those on anticancer targeted therapy (ongoing or completed) in breast cancer patients of the Cardiac Oncology Toxicity Registry (lower panel).</s></p></div></figDesc><graphic coords="3,151.18,398.25,245.20,292.72" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Prevalence of arterial hypertension, diabetes mellitus, smoking status, dyslipidemia, history of heart failure, and previous cardiac disease in the initial population of the Cardiac Oncology Toxicity Registry.</s><s>The term 'unknown' refers to patients in whom the specific information was not collected.</s></p></div></figDesc><graphic coords="4,74.08,242.70,411.88,453.64" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>List of active contributing countries</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>Baseline</cell><cell></cell></row><row><cell>Country</cell><cell cols="2">Enrolled patients (%)</cell><cell>Locked CRFs</cell></row><row><cell>Austria</cell><cell>10</cell><cell>0.8</cell><cell>7</cell></row><row><cell>Belgium</cell><cell>132</cell><cell>10.2</cell><cell>76</cell></row><row><cell>China</cell><cell>9</cell><cell>0.7</cell><cell>0</cell></row><row><cell>Cyprus</cell><cell>11</cell><cell>0.9</cell><cell>2</cell></row><row><cell>France</cell><cell>34</cell><cell>2.6</cell><cell>0</cell></row><row><cell>Georgia</cell><cell>12</cell><cell>0.9</cell><cell>11</cell></row><row><cell>Germany</cell><cell>28</cell><cell>2.2</cell><cell>17</cell></row><row><cell>Greece</cell><cell>38</cell><cell>2.9</cell><cell>29</cell></row><row><cell>Italy</cell><cell>662</cell><cell>51.2</cell><cell>481</cell></row><row><cell>Malta</cell><cell>19</cell><cell>1.5</cell><cell>10</cell></row><row><cell>The Netherlands</cell><cell>1</cell><cell>0.1</cell><cell>0</cell></row><row><cell>Norway</cell><cell>13</cell><cell>1.0</cell><cell>9</cell></row><row><cell>Portugal</cell><cell>85</cell><cell>6.6</cell><cell>63</cell></row><row><cell>Romania</cell><cell>68</cell><cell>5.3</cell><cell>46</cell></row><row><cell>Saudi Arabia</cell><cell>99</cell><cell>7.7</cell><cell>16</cell></row><row><cell>Serbia</cell><cell>50</cell><cell>3.9</cell><cell>0</cell></row><row><cell>Spain</cell><cell>23</cell><cell>1.8</cell><cell>16</cell></row><row><cell>Total</cell><cell>1294</cell><cell>100.0</cell><cell>783</cell></row><row><cell>CRFs, case report forms.</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Population synthesis regarding ADRC in the Cardiac Oncology Toxicity Registry</s></p></div></figDesc><table><row><cell>Type of ADRC</cell><cell>n</cell><cell>%</cell></row><row><cell>Surveillance of LV function</cell><cell>725</cell><cell>92.6</cell></row><row><cell>Confirmed diagnosis of ADRC</cell><cell>35</cell><cell>4.47</cell></row><row><cell>Suspected diagnosis of ADRC</cell><cell>23</cell><cell>2.9</cell></row><row><cell>Total</cell><cell>783</cell><cell>100.0</cell></row></table><note><p><s>ADRC, anticancer drug-related cardiotoxicity; LV, left ventricular.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">ESC Heart Failure 2017; 4: 312-318 DOI: 10.1002/ehf2.12162</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The EACVI/HFA thanks the EORP staff at the Heart House for their support.</s><s>Registry Executive Committee of the EURObservational Research Programme (EORP).</s><s>Data collection was conducted by the EORP department from the ESC by Rachid Mir Hassaine as Clinical Project Manager, Katell Lemaitre as Project Officer, Maryna Andarala as Data Manager and Statistican.</s><s>Overall activities were coordinated and supervised by Doctor Aldo P. Maggioni (EORP Scientific Coordinator).</s><s>All investigators listed in Supporting Information Appendix S1.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>The ESC-COT Registry will be funded by the ESC.</s><s>Since the start of EORP, the following companies have supported the</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting information</head><p><s>Supporting information may be found in the online version of this article.</s></p><p><s>Appendix S1.</s><s>Executive Committee, EORP Team and Investigators.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Steliarova-Foucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lortet-Tieulent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Coebergh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Comber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Forman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="1374" to="1403" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The impact of cisplatinum-based chemotherapy on ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer</title>
		<author>
			<persName><forename type="first">K</forename><surname>Murbraech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Solheim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Aulie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Fossa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Aakhus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">ESC Heart Fail</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="142" to="149" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Expecting the unexpected: right atrial mass in a transplant patient</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Akpek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ozdogru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Sahin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Inanc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yazici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Berk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Karaca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kalay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oguzhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ergin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="s">Protective effects of spironolactone against anthracycline</title>
		<imprint/>
	</monogr>
	<note>induced cardiomyopathy</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="81" to="89" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Authors/Task Force Members.; ESC Committee for Practice Guidelines (CPG): The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Zamorano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lancellotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rodriguez</forename><surname>Muñoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Aboyans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Asteggiano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Galderisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Habib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lenihan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Lip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lyon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Lopez</forename><surname>Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mohty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Piepoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Tamargo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Torbicki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Suter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2768" to="2801" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data</title>
		<author>
			<persName><forename type="first">A</forename><surname>Verdecchia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Francisci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Brenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gatta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Micheli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mangone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kunkler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="784" to="796" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer</title>
		<author>
			<persName><forename type="first">V</forename><surname>Brower</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="835" to="836" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer</title>
		<author>
			<persName><forename type="first">D</forename><surname>Slamon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Eiermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Robert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pienkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Press</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mackey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Glaspy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pawlicki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pinter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Valero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sauter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Von Minckwitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Visco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Buyse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bendahmane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tabah-Fisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Lindsay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Riva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Crown</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="page" from="1273" to="1283" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Voors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bueno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Cleland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Falk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>González-Juanatey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Harjola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Jankowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jessup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Linde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Nihoyannopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Parissis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pieske</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Riley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Rosano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Ruilope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ruschitzka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Rutten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Der Meer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2129" to="2200" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">EACVI/ HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/ HFA COT Registry)-EURObservational Research Program of the European Society of Cardiology</title>
		<author>
			<persName><forename type="first">P</forename><surname>Lancellotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Donal</forename><forename type="middle">E</forename><surname>Edvardsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Popescu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Farmakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Filippatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Habib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Maggioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Jerusalem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Galderisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J Cardiovasc Imaging</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="466" to="470" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Expert consensus for multi-modality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Plana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Galderisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Ewer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Scherrer-Crosbie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ganame</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">A</forename><surname>Sebag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Agler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Badano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Banchs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cardinale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Caver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cerqueira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Cara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Edvarsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Flamm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Force</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Griffin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>Jerusalem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Magalhães</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Marwick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Y</forename><surname>Sicari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Villarraga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Lancellotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J Cardiovasc Imaging</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1063" to="1093" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Ischemic heart disease after breast cancer radiotherapy</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Darby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ewertz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="page" from="2523" to="2527" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients</title>
		<author>
			<persName><forename type="first">C</forename><surname>Shapiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hardenbergh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Blanks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hauptman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Recht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Hayes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Henderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="3493" to="3951" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Registry: protocol update and preliminary results CW, van Leeuween FE. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hooning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Botma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Aleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baaijens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bartelink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Klijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cot</forename><surname>Taylor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="365" to="375" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Metabolic syndrome and breast cancer risk: a case-cohort study nested in a multicentre Italian cohort</title>
		<author>
			<persName><forename type="first">C</forename><surname>Agnoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Grioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sacerdote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ricceri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tumino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Frasca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Pala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mattiello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Chiodini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Iacoviello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Panico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Krogh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0128891</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Skeletal muscle weakness is related to insulin resistance in patients with chronic heart failure</title>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Turhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Leyva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rauchhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sandek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Jankowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">ESC Heart Fail</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="85" to="89" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">An update on the risk prediction and prevention of anticancer therapyinduced cardiotoxicity</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bhave</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Akhter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Rosen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="590" to="599" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">ICARO (Italian CARdio-Oncological) Network. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer</title>
		<author>
			<persName><forename type="first">G</forename><surname>Russo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cioffi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tuccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Boccardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Khoury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lestuzzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Maurea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Oliva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Faggiano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tarantini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cardiovasc Med</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="141" to="146" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
